M8W Stock Overview
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MediWound Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.40 |
52 Week High | US$15.40 |
52 Week Low | US$6.45 |
Beta | 0.94 |
1 Month Change | 28.33% |
3 Month Change | 67.39% |
1 Year Change | 46.67% |
3 Year Change | -47.37% |
5 Year Change | -50.00% |
Change since IPO | -74.80% |
Recent News & Updates
Recent updates
Shareholder Returns
M8W | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 13.2% | 3.0% | 1.3% |
1Y | 46.7% | -25.6% | 6.4% |
Return vs Industry: M8W exceeded the German Pharmaceuticals industry which returned -24.2% over the past year.
Return vs Market: M8W exceeded the German Market which returned 7.5% over the past year.
Price Volatility
M8W volatility | |
---|---|
M8W Average Weekly Movement | 9.1% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: M8W's share price has been volatile over the past 3 months.
Volatility Over Time: M8W's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 100 | Ofer Gonen | https://www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. Fundamentals Summary
M8W fundamental statistics | |
---|---|
Market cap | €136.80m |
Earnings (TTM) | -€6.21m |
Revenue (TTM) | €17.29m |
7.9x
P/S Ratio-22.0x
P/E RatioIs M8W overvalued?
See Fair Value and valuation analysisEarnings & Revenue
M8W income statement (TTM) | |
---|---|
Revenue | US$18.69m |
Cost of Revenue | US$15.11m |
Gross Profit | US$3.58m |
Other Expenses | US$10.29m |
Earnings | -US$6.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.73 |
Gross Margin | 19.15% |
Net Profit Margin | -35.94% |
Debt/Equity Ratio | 0% |
How did M8W perform over the long term?
See historical performance and comparison